Plain-English translation of NCT04231877 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment approach for aggressive B-cell lymphoma, a type of blood cancer. The study combines —a newer targeted medication—with standard chemotherapy drugs, and some patients will also receive an additional medication called . Researchers want to see if this combination is safe and more effective than chemotherapy alone for patients who have just been diagnosed.
Some aggressive lymphomas don't respond well enough to standard treatment alone, and patients need better options. This trial is exploring whether adding newer, targeted medications to traditional chemotherapy can improve outcomes and help more patients achieve remission.
You would receive intravenous infusions of the medication combination once every three weeks for up to 6 cycles (about 4–5 months total). Each treatment cycle includes chemotherapy drugs given over several days, plus the new medication. You'll have regular blood tests, heart imaging, and scans to monitor how the treatment is working and check for side effects. After treatment ends, you'll have follow-up visits for up to 5 years to track your long-term health.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States